1/Featuring some highlights from @douglaskrakower 's PEP/PrEP talk at the advanced STD intensive course today!
Let's start with this pretty slide on antimicrobial STI ppx after exposure
ARE YOU READY for some questions?!
#IDTwitter #IDMedED @ID_fellows
Let's start with this pretty slide on antimicrobial STI ppx after exposure
ARE YOU READY for some questions?!
#IDTwitter #IDMedED @ID_fellows
2/You are called by the ED for post-exposure ppx after sexual assault. What is your recommendation for a pt with severe type I allergy to cephalosporins?
CRO Ceftriaxone IM
AZM Azithromycin PO
MET Metronidazole PO
GENT Gentamicin IM
SPEC Spectinomycin IM
CIP Ciprofloxacin PO
CRO Ceftriaxone IM
AZM Azithromycin PO
MET Metronidazole PO
GENT Gentamicin IM
SPEC Spectinomycin IM
CIP Ciprofloxacin PO
3/ Answer was option 2 featuring gentamicin
Check out the options below
Won't cover HBV PEP recs for this tweetorial today!
Check out the options below
Won't cover HBV PEP recs for this tweetorial today!
4/ Next Q:
22yo cisgender woman presents for HIV PEP. No medical conditions, no home meds. What do you recommend?
TDF, tenofovir disoproxil fumarate
TAF, tenofovir alafenamide
22yo cisgender woman presents for HIV PEP. No medical conditions, no home meds. What do you recommend?
TDF, tenofovir disoproxil fumarate
TAF, tenofovir alafenamide
5/
CDC guidelines recommend #1 or #2. Check out this chart on the preferred options
No major studies with TAF for PEP. Alternatives are listed below. Options such as Darunavir/r are available, but RAL/DOL prob better tolerated
Link to CDC guidelines: https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf
CDC guidelines recommend #1 or #2. Check out this chart on the preferred options

No major studies with TAF for PEP. Alternatives are listed below. Options such as Darunavir/r are available, but RAL/DOL prob better tolerated
Link to CDC guidelines: https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf
6/
Have you ever wondered about biktarvy for PEP? Prelim results of a safety/tolerability study at Fenway Health looking at TAF as PrEP were reported at CROI 2020 @khmayer1
https://www.croiconference.org/abstract/safety-and-tolerability-of-once-daily-bic-ftc-taf-for-postexposure-prophylaxis/
Have you ever wondered about biktarvy for PEP? Prelim results of a safety/tolerability study at Fenway Health looking at TAF as PrEP were reported at CROI 2020 @khmayer1
https://www.croiconference.org/abstract/safety-and-tolerability-of-once-daily-bic-ftc-taf-for-postexposure-prophylaxis/
7/ Now onto HIV PrEP!
35yo cisgender MSM pt with 10 partners, rectal GC in the past 12m. Wants PrEP. No renal dz, hep B, sxs. You order HIV Ab/Ag, hep B/C serologies, Cr.
When do you start PrEP?
35yo cisgender MSM pt with 10 partners, rectal GC in the past 12m. Wants PrEP. No renal dz, hep B, sxs. You order HIV Ab/Ag, hep B/C serologies, Cr.
When do you start PrEP?
8/
Start that day!
Check out the poster and webcast for this study on immediate PrEP. Safe to rx now, d/c if labs abnl - the potential loss to f/u was substantial: https://www.croiconference.org/abstract/immediate-prep-initiation-new-york-city-sexual-health-clinics/
Start that day!
Check out the poster and webcast for this study on immediate PrEP. Safe to rx now, d/c if labs abnl - the potential loss to f/u was substantial: https://www.croiconference.org/abstract/immediate-prep-initiation-new-york-city-sexual-health-clinics/
9/
A paper that must be covered in any PrEP discussion: DISCOVER, which shows non-inferiority of FTC/TAF to FTC/TAF with slight different in side effect profile https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31065-5/fulltext?rss=yes
@khmayer1
A paper that must be covered in any PrEP discussion: DISCOVER, which shows non-inferiority of FTC/TAF to FTC/TAF with slight different in side effect profile https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31065-5/fulltext?rss=yes
@khmayer1
10/
Read more about TAF in PrEP from @douglaskrakower in this paper! https://pubmed.ncbi.nlm.nih.gov/31931525/
Another key point: transgender populations are relatively invisible in these PrEP studies. Here is a commentary from Doug in CID on this topic:
https://pubmed.ncbi.nlm.nih.gov/32766887/
Read more about TAF in PrEP from @douglaskrakower in this paper! https://pubmed.ncbi.nlm.nih.gov/31931525/
Another key point: transgender populations are relatively invisible in these PrEP studies. Here is a commentary from Doug in CID on this topic:
https://pubmed.ncbi.nlm.nih.gov/32766887/
11/
A quick reference for on-demand PrEP, "2-1-1"
Link to Ipergay study: https://www.nejm.org/doi/full/10.1056/nejmoa1506273
A quick reference for on-demand PrEP, "2-1-1"
Link to Ipergay study: https://www.nejm.org/doi/full/10.1056/nejmoa1506273
12/ Last Q:
28y cisgender woman has HIV+ cisgender male partner. He uses ART with undetectable VL. Sex 2x/wk. Do not want to use condoms. Your counseling about HIV transmission is that studies suggest that risk of HIV transmission is
28y cisgender woman has HIV+ cisgender male partner. He uses ART with undetectable VL. Sex 2x/wk. Do not want to use condoms. Your counseling about HIV transmission is that studies suggest that risk of HIV transmission is
13/
ZERO! Video from everyone's favorite Dr. Fauci in 2019
You can also read this @JAMA_current viewpoint from Dr. Fauci on U=U: https://jamanetwork.com/journals/jama/article-abstract/2720997
PARTNER: https://jamanetwork.com/journals/jama/fullarticle/2533066
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30418-0/fulltext
Opposites Attract:
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(18)30132-2/fulltext
ZERO! Video from everyone's favorite Dr. Fauci in 2019
You can also read this @JAMA_current viewpoint from Dr. Fauci on U=U: https://jamanetwork.com/journals/jama/article-abstract/2720997
PARTNER: https://jamanetwork.com/journals/jama/fullarticle/2533066
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30418-0/fulltext
Opposites Attract:
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(18)30132-2/fulltext
14/
STI PEP: empiric tx for GC/CT/trich + prevention of HBV, HIV
HIV PEP+PrEP=effective, underused but inequities exist
TDF-FTC, TAF-FTC PrEP both
; minor safety diff
2-1-1 PrEP effective; only for MSM
U=U is the real deal
Long-acting PrEP, others coming soon






